Clinical Trial: HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06386263) titled 'HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada' on April 3.

Brief Summary: Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-Breast trials and has a marketing authorization from Health Canada for patients with HER2-positive metastatic breast cancer (mBC) and HER2-low mBC, respectively.

Multiple stakeholders, including clinicians, patients, regulators, and healthcare decision makers, are interested in real-world treatment-related outcomes in order to better represent the effectiveness of therapies in routine care settings.

Study Type: Observational

Condition: * Unresectab...